EQL PHARMA AB Cash Flow Conversion Efficiency
EQL PHARMA AB cash flow conversion efficiency. Based on the latest financial reports, EQL PHARMA AB (7JK) has a cash flow conversion efficiency ratio of 0.063x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€16.79 Million ≈ $19.63 Million USD) by net assets (€267.06 Million ≈ $312.22 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of EQL PHARMA AB (2022–2026)
Cash flow conversion efficiency of EQL PHARMA AB from 2022 to 2026. This chart illustrates how EQL PHARMA AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for EQL PHARMA AB for real-time trading data and today's change.
EQL PHARMA AB Cash Flow Conversion Ratio Explained
EQL PHARMA AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
EQL PHARMA AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of EQL PHARMA AB ranked by their cash flow conversion efficiency. Also see market value of EQL PHARMA AB for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Inversa Prime SOCIMI S.A.
MC:YIPS
|
-0.029x |
|
Newfield Resources Ltd
AU:NWF
|
0.201x |
|
DHP Korea Co. Ltd
KQ:131030
|
0.035x |
|
iLearningEngines, Inc.
NASDAQ:AILE
|
-3.216x |
|
American Lithium Corp
V:LI
|
-0.019x |
|
Garuda Indonesia Persero Tbk
JK:GIAA
|
-0.041x |
|
Tomei Consolidated Bhd
KLSE:7230
|
-0.004x |
|
Herige SA
PA:ALHRG
|
0.119x |
Annual Cash Flow Conversion Efficiency for EQL PHARMA AB (2022–2026)
The table below shows the annual cash flow conversion efficiency of EQL PHARMA AB from 2022 to 2026. Review EQL PHARMA AB free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | €267.06 Million ≈ $312.22 Million |
€28.36 Million ≈ $33.16 Million |
0.106x | +195.22% |
| 2025-03-31 | €221.03 Million ≈ $258.41 Million |
€-24.65 Million ≈ $-28.82 Million |
-0.112x | -73.31% |
| 2024-03-31 | €177.73 Million ≈ $207.78 Million |
€-11.44 Million ≈ $-13.37 Million |
-0.064x | -136.06% |
| 2023-03-31 | €154.75 Million ≈ $180.92 Million |
€27.62 Million ≈ $32.29 Million |
0.178x | -47.26% |
| 2022-03-31 | €123.63 Million ≈ $144.53 Million |
€41.83 Million ≈ $48.90 Million |
0.338x | -- |
About EQL PHARMA AB
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers prescription drugs, including hospital products. EQL Pharma AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.